An Investigation of the Safety of Continued Treatment with Sorafenib in Patients with Unresectable Hepatocellular Carcinoma after the First Disease Progression
Phase of Trial: Phase II
Latest Information Update: 11 May 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 11 May 2015 Primary endpoint, safety (incidence of adverse events) between PD1 and PD2 not a concern
- 10 Oct 2013 Planned end date (30 Jun 2014) as reported by ClinicalTrials.gov.
- 10 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.